Slide background

Novadip Biosciences, an advanced biopharmaceutical company focused on
new generation of therapies from adipose stem cells adapted to hard and soft tissues reconstruction.


CREOST® is a patented cellular therapy to provide innovative treatments for bone healing disorders and bone defects. The product is made of Adipose-derived Mesenchymal Stem Cells (AMSCs) obtained after their isolation from a minimally invasive subcutaneous procedure. A 3 dimensional implant is obtained after pre-differentiation of AMSCs and by addition of a proprietary quality. CREOST®

Read More

Our Achievements

Since 2013, Novadip Biosciences develops breakthrough innovative in cell-based therapies. Its first mission is to treat patients with critical size bone defects and bone diseases. Today we have two proof of concept studies on large pre-clinical models (pigs) and clinical results on 15 patients treated with our new autologous 3 dimensional tissue implant for bone

Read More

Market Application

Critical size bone defects following trauma, infection, congenital deficiency  or carcinologic resection remain a major healthcare issue because of difficulties in reconstructing large bone segments by using bone implants with poorly controlled osteoinduction and  disappointing osteogenic properties. CREOST® is a medical solution to reconstruct large bone defect for a long term improvement of quality of life

Read More


Recent News

Novadip is hiring!

You want to be part of a growing innovative biotech company ? Check out our vacant positions here.

Read More
Novadip closes EUR 28 million Series A Round with US and Belgian investors to advance breakthrough cell therapy pipeline

EN – FR – NL Louvain-la-Neuve, Belgium – September 10, 2015 – Novadip Biosciences, a biopharmaceutical spin-off company of Université catholique de L

Read More
La Libre : La biopharmacie belge en mal de capital risque.

Novadip, parcours du combattant

Read More